Peter Olson

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 16 papers. Top paper: “Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor”.

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor

Journal of Medicinal Chemistry(2021)10.1021/acs.jmedchem.1c01688

N/A

10.9DataRank · unranked

731 citations

Shelley Allen, James F. Blake, Vickie Bowcut, David M. Briere, Andrew Calinisan +23 more

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0177

N/A

0.828DataRank · unranked

248 citations

Megan T. Hoffman, Laleh Abbassi, Ziyue Li, Francesca Paradiso, Brendan D. Parent +50 more

Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma

Nature Communications(2023)10.1038/s41467-023-38342-7

N/A

0.587DataRank · unranked

49 citations

Pavlos Msaouel, Cara Haymaker, Surena F. Matin, Matthew T. Campbell, Amado J. Zurita +17 more

Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial

Nature Communications(2025)10.1038/s41467-024-55642-8

N/A

0.406DataRank · unranked

12 citations

Herbert Yu, Ying Yuan, Jianfeng Chen, Xinmiao Yan, Menuka Karki +22 more

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

European Urology Oncology(2024)10.1016/j.euo.2023.12.001

N/A

0.360DataRank · unranked

10 citations

Randy F. Sweis, Manojkumar Bupathi, Elisabeth Heath, Oscar B. Goodman, Christopher J. Hoimes +19 more

Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography

Journal of Medicinal Chemistry(2023)10.1021/acs.jmedchem.3c02140

N/A

0.330DataRank · unranked

8 citations

Dan Chen, James G. Christensen, René Coulombe, James Féthière, Robin J. Gunn +16 more

Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors

Bioorganic & Medicinal Chemistry(2022)10.1016/j.bmc.2022.116947

N/A

0DataRank · unranked

15 citations

Ruth Aranda, James G. Christensen, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac +10 more

A Non-covalent KRASG12D Allele Specific Inhibitor Demonstrates Potent Inhibition of KRAS-dependent Signaling and Regression of KRASG12D-mutant Tumors

Research Square(2022)10.21203/rs.3.rs-1261963/v1

N/A

0DataRank · unranked

1 citations

Jill Hallin, Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis +25 more

Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.03.21.436338

N/A

0DataRank · unranked

15 citations

Shuai Li, Alireza Khodadadi‐Jamayran, Jayu Jen, Han Han, Kayla Guidry +11 more

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Nature Medicine(2022)10.1038/s41591-022-02007-7

N/A

0DataRank · unranked

519 citations

Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis, Lars D. Engstrom +25 more

Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0369

N/A

0DataRank · unranked

103 citations

Shuai Li, Alireza Khodadadi‐Jamayran, Jayu Jen, Han Han, Kayla Guidry +13 more

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0870

N/A

0DataRank · unranked

33 citations

Larry Yan, Fadia Qiryaqos, Lars D. Engstrom, Jade Laguer, Andrew Calinisan +29 more

Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein

Journal of Medicinal Chemistry(2024)10.1021/acs.jmedchem.4c00078

N/A

0DataRank · unranked

21 citations

Stephen J. Harwood, Ruth Aranda, Athenea N. Aloiau, Briana M. Bobek, David M. Briere +25 more

Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2310

N/A

0DataRank · unranked

21 citations

Alvaro G. Paula, David Molkentine, Laura D. Hover, Monique B. Nilsson, Natalie I. Vokes +17 more

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction

Journal of Medicinal Chemistry(2022)10.1021/acs.jmedchem.2c00741

N/A

0DataRank · unranked

95 citations

Jacob R. Haling, Shilpi Khare, Vickie Bowcut, David M. Briere, Aaron C. Burns +21 more

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP -Deleted Cancers

Journal of Medicinal Chemistry(2022)10.1021/acs.jmedchem.1c01900

N/A

0DataRank · unranked

152 citations

Ruth Aranda, Thomas P. Bobinski, David M. Briere, Aaron C. Burns, James G. Christensen +18 more